Sagar Lonial, MD, Winship Cancer Institute of Emory University, Atlanta, GA, talks on the first results of iberdomide, a potent cereblon E3 ligase modulator, in combination with dexamethasone (dex) and daratumumab (dara) or bortezomib in patients with relapsed/refractory multiple myeloma. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.